Kobayashi Pharmaceutical Co Stock Probability Of Bankruptcy
| KBYPFDelisted Stock | USD 32.49 0.00 0.00% |
Kobayashi |
Kobayashi Pharmaceutical Co Company chance of financial distress Analysis
Kobayashi Pharmaceutical's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Kobayashi Pharmaceutical Probability Of Bankruptcy | Over 100% |
Most of Kobayashi Pharmaceutical's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kobayashi Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Kobayashi Pharmaceutical probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Kobayashi Pharmaceutical odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Kobayashi Pharmaceutical Co financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Kobayashi Pharmaceutical Co has a Probability Of Bankruptcy of 100%. This is 176.4% higher than that of the Consumer Defensive sector and 186.45% higher than that of the Household & Personal Products industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Kobayashi Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kobayashi Pharmaceutical's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kobayashi Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kobayashi Pharmaceutical by comparing valuation metrics of similar companies.Kobayashi Pharmaceutical is currently under evaluation in probability of bankruptcy category among its peers.
Kobayashi Fundamentals
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 3.94 B | |||
| Shares Outstanding | 76.01 M | |||
| Shares Owned By Insiders | 34.50 % | |||
| Shares Owned By Institutions | 21.77 % | |||
| Price To Earning | 34.29 X | |||
| Price To Book | 2.85 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 155.25 B | |||
| Gross Profit | 88.77 B | |||
| EBITDA | 32.49 B | |||
| Net Income | 19.71 B | |||
| Cash And Equivalents | 116.15 B | |||
| Total Debt | 596 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.92 X | |||
| Book Value Per Share | 2,653 X | |||
| Cash Flow From Operations | 22.42 B | |||
| Earnings Per Share | 1.94 X | |||
| Number Of Employees | 3.45 K | |||
| Beta | 0.27 | |||
| Market Capitalization | 5.37 B | |||
| Total Asset | 252.55 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 252.55 B | |||
| Last Dividend Paid | 84.0 |
About Kobayashi Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kobayashi Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kobayashi Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kobayashi Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Kobayashi Pink Sheet
If you are still planning to invest in Kobayashi Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kobayashi Pharmaceutical's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |